Alzheon Inc., a clinical-level biopharmaceutical company upgrading in diagnostics and therapeutics for the Alzheimer’s disease (AD) patient group, has confirmed that they will present new safety and efficacy data from the Phase 2 study, lasting for over 3 years. The company will also present a quantitative systems pharmacology (QSP) analysis for its popular valiltramiprosate/ALZ-801, an investigational therapy at the San Diego, California, Clinical Trials on Alzheimer’s Disease (CTAD) conference during its 18th most successful event and a round of effective discussion.
Valiltramiprosate is a potential investigational oral therapeutic candidate in the Phase 3 trials. This oral therapeutic works against anti-amyloid antibodies by avoiding neurotoxic amyloid oligomer formation. This oral works as a prodrug of tramiprosate with enhanced brain penetration and pharmacokinetics that focus on early amyloid aggregation. This is essential in Alzheimer’s disease progression.
It also focuses on the functions in people showing early-stage Alzheimer’s disease and preserves cerebral structure with a specific attention on APOE4/4 homozygotes. The homozygotes are the ones with the peak genetic risk group and have a history of a merge disease progression with lacked treatment options.
PhD, Founder and Principal Investigator at Alzheimer’s & Research Treatment Center, David Watson, said, “The promising structural and clinical brain outcomes from the APOLLOE4 Phase 3 program are on a consistent track to power up the case for valiltramiprosate as a strong, groundbreaking oral treatment for the peak risk APOE4 group. The therapies holding safety to mitigate the formation of toxic amyloid oligomers at the beginning of the disease process have the best chance to make the right decision on how and when we treat Alzheimer’s disease.”
The Quantitative Systems Pharmacology (QSP) analysis of long-standing extended valiltramiprosate clinical data to be present at CTAD is expected to show preservation of hippocampal volume and the vast fall in neurodegeneration. The data stick to a valuable lower speed of clinical disagreement in early symptomatic AD. The studies confirm that valiltramiprosate gathers monomeric beta amyloid, and stops the generative hazardous oligomers linked with neuron loss and synaptic toxicity.
The PhD, Chief Scientific Officer at Alzheon, John Hey, said, “These new findings are a contribution to our upstream idea in trimming the course of Alzheimer’s disease and spotlight valiltramiprosate’s potency as a valuable, effective and safe oral therapy for patients with APOE4. The continuous imaging, molecular and clinical modelling data deliver a strong basis for precision medicine development and regulatory discussions of our key product.”
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
